(5-Acetamido-3,4-diacetyloxy-6-ethoxyoxan-2-yl)methyl acetate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (5-Acetamido-3,4-diacetyloxy-6-ethoxyoxan-2-yl)methyl acetate
• 化学式: C₁₆H₂₅NO₉
• mdl: MFCD01118824
• 分子量: 375.37
• InChiKey: POOQFLLMEIHRRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• N-ACETYGLUCOSAMINE DERIVATIVES AND USE THEREOF
  申请人：MIURA Kyoko

  公开号：US20080293673A1

  公开（公告）日：2008-11-27

  The present invention relates to An N-acetylglucosamine derivative represented by the following formula (1), and a hyaluronic acid production promoting agent containing the same and a skin external preparation containing the same: wherein R 1 is a hydrogen atom or an alkyl group having 2 to 18 carbon atoms; R 2 , R 3 , and R 4 are hydrogen atoms or acyl groups having 2 to 18 carbon atoms and may be all the same or different from others; the steric structure at position 1 may be α or β; provided that R 1 , R 2 , R 3 , and R 4 must not be all hydrogen atoms. It is intended to provide an easily available hyaluronic acid production promoting agent and a skin external preparation whereby the production of hyaluronic acid can be promoted in the skin and thus the skin can be maintained in a vital and moist state so that it is expected that the human skin can be prevented from age.

  本发明涉及以下式（1）所表示的N-乙酰葡萄糖氨衍生物，以及含有该衍生物的透明质酸生产促进剂和皮肤外用制剂：其中，R1是氢原子或具有2至18个碳原子的烷基；R2、R3和R4是氢原子或具有2至18个碳原子的酰基，可以全部相同或不同；位置1的立体结构可以是α或β；前提是R1、R2、R3和R4不能全部是氢原子。旨在提供一种易于获得的透明质酸生产促进剂和皮肤外用制剂，通过促进皮肤中透明质酸的产生，从而使皮肤保持活力和湿润状态，预防人体皮肤老化。
• SIRNA, PHARMACEUTICAL COMPOSITION AND CONJUGATE WHICH CONTAIN SIRNA, AND USES THEREOF
  申请人：Suzhou Ribo Life Science Co., Ltd.

  公开号：EP3315608A1

  公开（公告）日：2018-05-02

  Disclosed are a small interfering nucleic acid specifically inhibiting HBV gene expression, and a pharmaceutical composition and a siRNA conjugate which contain the small interfering nucleic acid and can be used for preventing and/or treating hepatitis B. Also provided is a use of the small interfering nucleic acid in preparing drugs for preventing and/or treating hepatitis B.

  公开了一种特异性抑制 HBV 基因表达的小干扰核酸，以及一种含有该小干扰核酸并可用于预防和/或治疗乙型肝炎的药物组合物和 siRNA 结合物。
• COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3524680A1

  公开（公告）日：2019-08-14

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供的是具有共轭基团的低聚化合物。在某些实施方案中，低聚化合物与 N-乙酰半乳糖胺共轭。
• CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3546579A1

  公开（公告）日：2019-10-02

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供的是具有共轭基团的低聚化合物。在某些实施方案中，低聚化合物与 N-乙酰半乳糖胺共轭。
• NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE
  申请人：Suzhou Ribo Life Science Co., Ltd.

  公开号：EP3719125A1

  公开（公告）日：2020-10-07

  Provided are a siRNA for inhibiting the expression of hepatitis B virus gene, and a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is independently a modified nucleotide. The siRNA comprises a sense strand and an antisense strand. The sense strand of the siRNA comprises a nucleotide sequence 1 having the same length and no more than three nucleotides different from the nucleotide sequence shown in SEQ ID NO: 155, and the antisense strand of the siRNA comprises a nucleotide sequence 2 having the same length and no more than three nucleotides different from the nucleotide sequence shown in SEQ ID NO: 156.

  本文提供了一种用于抑制乙型肝炎病毒基因表达的 siRNA，以及含有该 siRNA 的药物组合物和共轭物。 siRNA 中的每个核苷酸都是独立的修饰核苷酸。 siRNA 包括有义链和反义链。 siRNA 的有义链包括与 SEQ ID NO: 155 所示核苷酸序列具有相同长度且相差不超过三个核苷酸的核苷酸序列 1，而 siRNA 的无义链包括与 SEQ ID NO: 156 所示核苷酸序列具有相同长度且相差不超过三个核苷酸的核苷酸序列 2。